565 related articles for article (PubMed ID: 28485683)
1. Cardiac complications in beta-thalassemia: From mice to men.
Kumfu S; Fucharoen S; Chattipakorn SC; Chattipakorn N
Exp Biol Med (Maywood); 2017 Jun; 242(11):1126-1135. PubMed ID: 28485683
[TBL] [Abstract][Full Text] [Related]
2. Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity.
Lekawanvijit S; Chattipakorn N
Can J Cardiol; 2009 Apr; 25(4):213-8. PubMed ID: 19340344
[TBL] [Abstract][Full Text] [Related]
3. Cardiomyopathy associated with iron overload: how does iron enter myocytes and what are the implications for pharmacological therapy?
Wijarnpreecha K; Kumfu S; Chattipakorn SC; Chattipakorn N
Hemoglobin; 2015; 39(1):9-17. PubMed ID: 25572185
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial calcium uniporter blocker prevents cardiac mitochondrial dysfunction induced by iron overload in thalassemic mice.
Kumfu S; Chattipakorn S; Fucharoen S; Chattipakorn N
Biometals; 2012 Dec; 25(6):1167-75. PubMed ID: 22910858
[TBL] [Abstract][Full Text] [Related]
5. Heart Rate Variability for Early Detection of Iron Overload Cardiomyopathy in β-Thalassemia Patients.
Koonrungsesomboon N; Tantiworawit A; Phrommintikul A; Saekho S; Srichairattanakool S; Chattipakorn N
Hemoglobin; 2015; 39(4):281-6. PubMed ID: 26029793
[TBL] [Abstract][Full Text] [Related]
6. Physiology and pathophysiology of iron cardiomyopathy in thalassemia.
Wood JC; Enriquez C; Ghugre N; Otto-Duessel M; Aguilar M; Nelson MD; Moats R; Coates TD
Ann N Y Acad Sci; 2005; 1054():386-95. PubMed ID: 16339687
[TBL] [Abstract][Full Text] [Related]
7. Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Pinto VM; Forni GL
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233561
[TBL] [Abstract][Full Text] [Related]
8. Increased sympathovagal imbalance evaluated by heart rate variability is associated with decreased T2* MRI and left ventricular function in transfusion-dependent thalassemia patients.
Pattanakuhar S; Phrommintikul A; Tantiworawit A; Konginn S; Srichairattanakool S; Chattipakorn SC; Chattipakorn N
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29330222
[TBL] [Abstract][Full Text] [Related]
9. Cardiac involvement in beta-thalassaemia: current treatment strategies.
Paul A; Thomson VS; Refat M; Al-Rawahi B; Taher A; Nadar SK
Postgrad Med; 2019 May; 131(4):261-267. PubMed ID: 31002266
[TBL] [Abstract][Full Text] [Related]
10. Cardiac complications and iron overload in beta thalassemia major patients-a systematic review and meta-analysis.
Koohi F; Kazemi T; Miri-Moghaddam E
Ann Hematol; 2019 Jun; 98(6):1323-1331. PubMed ID: 30729283
[TBL] [Abstract][Full Text] [Related]
11. Electrocardiographic Presentation, Cardiac Arrhythmias, and Their Management in β-Thalassemia Major Patients.
Russo V; Rago A; Papa AA; Nigro G
Ann Noninvasive Electrocardiol; 2016 Jul; 21(4):335-42. PubMed ID: 27324981
[TBL] [Abstract][Full Text] [Related]
12. Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice.
Khamseekaew J; Kumfu S; Wongjaikam S; Kerdphoo S; Jaiwongkam T; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
Eur J Pharmacol; 2017 Mar; 799():118-127. PubMed ID: 28192097
[TBL] [Abstract][Full Text] [Related]
13. Congestive heart failure and treatment in thalassemia major.
Aessopos A; Kati M; Tsironi M
Hemoglobin; 2008; 32(1-2):63-73. PubMed ID: 18274984
[TBL] [Abstract][Full Text] [Related]
14. Iron and oxidative stress in cardiomyopathy in thalassemia.
Berdoukas V; Coates TD; Cabantchik ZI
Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
[TBL] [Abstract][Full Text] [Related]
15. Bimodal cardiac dysfunction in an animal model of iron overload.
Yang T; Dong WQ; Kuryshev YA; Obejero-Paz C; Levy MN; Brittenham GM; Kiatchoosakun S; Kirkpatrick D; Hoit BD; Brown AM
J Lab Clin Med; 2002 Oct; 140(4):263-71. PubMed ID: 12389025
[TBL] [Abstract][Full Text] [Related]
16. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives.
Kremastinos DT; Farmakis D; Aessopos A; Hahalis G; Hamodraka E; Tsiapras D; Keren A
Circ Heart Fail; 2010 May; 3(3):451-8. PubMed ID: 20484195
[TBL] [Abstract][Full Text] [Related]
17. Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia.
Anderson ER; Taylor M; Xue X; Ramakrishnan SK; Martin A; Xie L; Bredell BX; Gardenghi S; Rivella S; Shah YM
Proc Natl Acad Sci U S A; 2013 Dec; 110(50):E4922-30. PubMed ID: 24282296
[TBL] [Abstract][Full Text] [Related]
18. Effects of the iron chelator deferiprone and the T-type calcium channel blocker efonidipine on cardiac function and Ca
Khamseekaew J; Kumfu S; Palee S; Wongjaikam S; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
Cell Calcium; 2018 Jun; 72():18-25. PubMed ID: 29748130
[TBL] [Abstract][Full Text] [Related]
19. Beta-thalassemia heart disease: is it time for its recognition as a distinct cardiomyopathy?
Kremastinos DT
Hellenic J Cardiol; 2008; 49(6):451-2. PubMed ID: 19110935
[No Abstract] [Full Text] [Related]
20. Evidence for a novel mechanism independent of myocardial iron in β-thalassemia cardiac pathogenesis.
Stoyanova E; Cloutier G; Felfly H; Lemsaddek W; Ah-Son N; Trudel M
PLoS One; 2012; 7(12):e52128. PubMed ID: 23284899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
